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Introduction
Systemic sclerosis (SSc) is a connective tissue dis-
ease clinically characterized by different degrees of
skin fibrosis and visceral organ involvement (17, 19,
22). The etiology of SSc remains obscure; the disease
appears to be the result of a multistep and multifac-
torial process, including immune system alterations,
genetic and exogenous, and toxic or infectious fac-
tors (17, 19, 22). The epidemiology of SSc is not defi-
nitely established due to the relative rarity of the
disease, the difficulty in diagnosis, and its extreme
clinical variability. SSc affects females more fre-
quently than males, with a peak of incidence between
ages 45 and 64 years (19, 22). There seems to be an
increased incidence of the disease in blacks, particu-
larly in black females, but no other significant racial
differences in distribution. Various HLA studies in
SSc patients failed to identify any clearcut associa-
tions, even if a role of specific HLA antigens might 
be hypothesized for particular clinico-serologic SSc
subsets (19). Moreover, familial factors are certainly
important for SSc development: it is not rare to ob-
serve a scleroderma patient with 1 or more first-
degree relatives with another autoimmune systemic
disorder, such as Raynaud phenomenon, systemic lu-
pus, or rheumatoid arthritis (19, 22). 
The annual incidence (new cases/population at
risk per year) of SSc varies largely among different
surveys (from 0.6 to 19.1 per million/year), as does
the estimated prevalence (number of cases living at
a particular time or during a given time interval per
million of population at risk: from 126 to 1,500). The
actual incidence and prevalence of the disease are
generally underestimated; the minimum estimated
values are 20/million per year and 1,500/million, re-
spectively. The number of undiagnosed cases, espe-
cially in the oldest surveys, might be significant; this
is due, at least in part, to the clinical characteristics
of the disease. SSc includes a wide spectrum of
symptoms, varying from very mild cutaneous and in-
ternal organ involvement to diffuse fibrosis responsi-
ble for organ failure (4, 11, 17, 19, 22). 
A variable combination of organ damage, or, less
frequently, a severe, single organ involvement, is re-
sponsible for SSc morbidity and mortality. Among
different connective tissue diseases, SSc shows the
poorest prognosis (17, 19, 22). The availability of
well-recognized criteria for diagnosis, disease activ-
ity (34), and severity (21), as well as of valuable prog-
nostic parameters, should be decisive for timely
patient identification, clinical assessment, and man-
agement. In the absence of valuable diagnostic crite-
ria, patients are usually classified according to the
American College of Rheumatology (formerly ARA)
preliminary criteria for SSc classification (32) (Table
1). The introduction of capillaroscopic SSc pattern
(capillary dilation with or without capillary drop-
outs) and SSc-related serum autoantibodies might
improve the usefulness of classification criteria, par-
ticularly in discriminating the early stage of the dis-
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ease. However, these criteria are not intended to as-
sist in the diagnosis of individual patients, which is
based on the careful observation of different clinical
and laboratory features. 
Diagnosis of SSc in patients with diffuse cutaneous
sclerosis is quite easy; on the contrary, it can be par-
ticularly difficult during the early stage of the disease
or in the presence of sine scleroderma SSc (ssSSc)
(Figure 1). In these instances, isolated Raynaud phe-
nomenon (Table 2) or other connective tissue dis-
eases must be ruled out. Diagnosis of SSc is currently
based on the presence of cutaneous manifestations
(symmetrical, truncal, and/or acral skin sclerosis,
skin ulcers, digital pitting scars, telangiectasias, cal-
cinosis), typical internal organ involvement (lung fi-
brosis, esophageal dysfunction, heart and/or renal
alterations), capillaroscopic scleroderma pattern,
and autoantibody profile (see Table 1, Figures 1–3). 
The large variability in the disease course, gener-
ally characterized by progressive, often subclinical,
visceral organ deterioration, makes the long-term
outcome of SSc extremely unpredictable. The clini-
cal and autoantibody pattern of the disease observed
in different patient populations may also vary widely
(2, 8, 10–15, 17, 19, 22, 30, 31, 35). The relationship be-
tween clinico-serologic features of SSc and survival
rates can give us useful prognostic parameters.
Moreover, follow-up studies on different patient se-
ries can yield new insights on the possible variations
of SSc pathomorphism during the last few decades.
These changes could be the consequence of different
racial and etiopathogenetic factors, as well as of
improved therapeutic strategies. In this light, we ret-
rospectively investigated demographic and clinico-
serologic features in a large cohort of Italian patients
with SSc, and their relationship to survival.
Patients and Methods
In 1997 the Italian Society of Rheumatology (SIR) promoted the
present study involving 3 University-based divisions of rheuma-
tology from the north (University of Padova), center (University of
Pisa), and south (University of Napoli) of Italy with comparable,
long-term experience in SSc patient management.
Patients
The study population was recruited between 1955 and 1999 at
the 3 participating centers. One thousand twelve patients (897 fe-
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TABLE 1. Classification criteria and diagnostic
parameters of systemic sclerosis (SSc)
Preliminary Main 
Classification Criteria* Diagnostic Parameters
Major criterion Proximal skin sclerosis
Proximal scleroderma Sclerodactyly
Minor criteria Raynaud phenomenon
Sclerodactyly Digital pitting scars
Digital pitting scars Bibasilar pulmonary fibrosis
Bibasilar pulmonary fibrosis Esophageal dysfunction
Telangiectasias
Calcinosis
Capillaroscopic SSc pattern
Serum autoantibodies†
*American College of Rheumatology (formerly ARA) 1980 Cri-
teria (ref. 32): the major criterion or any combination of 2 or more
minor criteria was found in 97% of definite SSc patients (sensitiv-
ity) and in 2% of comparison cases (98% specificity). Localized
scleroderma and pseudoscleroderma disorders represent criteria
of exclusion.
†Anti-Scl70, anti-centromere, anti-nucleolar antibodies.
FIG. 1. Systemic sclerosis (SSc) classification according to skin
sclerosis extent (black areas). Sine scleroderma SSc (ssSSc): ab-
sence of cutaneous sclerosis in patients with typical SSc visceral
organ involvement, capillaroscopic changes, and serum autoanti-
bodies. Limited cutaneous scleroderma (lcSSc): skin sclerosis of
fingers (sclerodactyly) with or without mild sclerotic lesions at
neck, face, and armpits. Intermediate cutaneous scleroderma 
(icSSc): sclerosis of upper and lower limbs, neck and face, with-
out truncal involvement. Diffuse cutaneous scleroderma (dcSSc):
distal and truncal skin sclerosis.
TABLE 2. Approach to apparently isolated 
Raynaud phenomenon
1. Exclusion of other conditions
2. Accurate history and complete physical examination to iden-
tify any sign or symptom of connective tissue disease (arthri-
tis, dysphagia, telangiectasias, digital ulcers, or pitting scars,
calcinosis)
3. Nailfold capillaroscopy
4. Autoantibody detection
Raynaud phenomenon (RP) classification
Type I: Primary, isolated RP
Type II: Suspected secondary RP. Presence of 1 or more
clinical, serologic, or capillaroscopic alterations not
sufficient for diagnosis of definite disease
Type III: Secondary RP
males, 115 males; mean age at presentation, 50.5  13.8 SD years;
see Table 3) were included in the study; namely, 323 patients from
Padova were collected between 1978 and 1999, 349 from Pisa be-
tween 1972 and 1999, and 340 from Napoli between 1955 and 1999.
At the beginning of the follow-up, corresponding to the time of
diagnosis, all patients fulfilled the American College of Rheuma-
tology (formerly ARA) criteria for SSc classification (32; see Table
1). At the same time, patients were also classified based on the ex-
tent of skin sclerosis according to the 3-cutaneous subset model
(18). These subsets are 1) limited cutaneous scleroderma (lcSSc):
sclerosis of fingers with or without sclerosis of the neck and/or
face; 2) intermediate cutaneous scleroderma (icSSc): sclerosis of
upper and lower limbs, neck, and face, without truncal involve-
ment; and 3) diffuse cutaneous scleroderma (dcSSc): distal and
truncal skin sclerosis (see Figure 1). For the survival study pa-
tients were also grouped according to the 2-cutaneous subset clas-
sification (17, 19, 22, 31); namely, patients were classified as having
limited cutaneous scleroderma (sclerosis of distal extremities, not
above the elbow and knees, with or without sclerosis of neck and
face) or diffuse cutaneous scleroderma (sclerosis of both distal
and proximal extremities, with or without truncal involvement).
Patients with ssSSc were invariably included in the lcSSc subset
(12, 26).
Clinical assessment
Epidemiologic and clinico-serologic assessment was carried
out at different centers using data from patient records in 3 main
categories: demographic data and symptoms at SSc onset, clinical
features observed at the time of referral, and cumulative clinical
manifestations observed during the entire follow-up.
Standardized criteria were followed for the evaluation of clini-
cal symptoms (11, 12). In particular, the age at disease onset was
considered to be the age at which the first signs and symptoms
compatible with the disease appeared; namely, Raynaud with dig-
ital ischemic lesions, puffy hands, sclerodactyly with or without
proximal scleroderma, dyspnea, and/or dysphagia.
Organ involvement was evaluated according to the criteria pre-
viously described (11, 12) with some modifications. In particular,
each type of involvement was defined as follows: 1) peripheral vas-
cular: Raynaud phenomenon with digital pitting scars (see Figure
3) and/or ulcerations or gangrene; 2) joint: presence of poly-
arthralgia or arthritis when inflammatory changes were observed
in more than 2 joints; 3) muscle: isolated muscle weakness or
weakness associated with elevated serum creatine kinase with or
without electromyographic or histologic changes of inflammatory
myopathy; 4) esophageal: dysphagia and or esophageal radio-
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FIG. 2. Capillaroscopic findings. a. Normal subject. b. Patient with isolated Raynaud phenomenon. c. and d. Typical scleroderma pat-
terns: c. diffuse capillary enlargement (megacapillaries), d. presence of megacapillaries and large avascular areas (capillary dropouts).
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FIG. 3. Cutaneous manifestations of SSc. A. Patient with limited cutaneous SSc (lcSSc): mild perioral sclerosis and diffuse telangiec-
tasias. B. Patient with diffuse cutaneous SSc: marked skin sclerosis at face and neck, diffuse hypermelanosis with some hypochromic ar-
eas. C. Digital pitting scars and pulp ulcers in lcSSc. D. Subcutaneous calcinosis at knees in lcSSc.
A B
C D
graphic dysmotility; 5) pulmonary: bibasilar fibrosis at standard
chest X-ray and/or restrictive lung disease on pulmonary function
tests and/or pulmonary hypertension; 6) cardiac: at least 1 of the
following symptoms: pericarditis, congestive heart failure, severe
arrhythmias, and/or atrioventricular conduction abnormalities; 7)
renal: scleroderma renal crisis with increased diastolic blood pres-
sure and/or progressive renal failure.
Laboratory findings
At the beginning and/or during the follow-up, the presence of
serum autoantibodies was investigated in 755 SSc patients by
means of standard techniques (11, 12): antinuclear (ANA) and anti-
nucleolar antibodies (ANoA) by indirect immunofluorescence on
rat liver (dilution 1:20) and/or on Hep-2 cell lines (dilution 1:40);
anticentromere antibodies (ACA); antiextractable nuclear antigen
(ENA) antibodies, including anti-Scl70, -Sm, -RNP, -SSA/SSB.
Routine blood chemistry and urinalysis were also performed at
the first visit and at regular time intervals during follow-up.
Survival rates
During 1999 the vital status of all patients lost to follow-up was
established by contacting the patients themselves or relatives,
their primary care physician, or the municipal death registry.
For patients known to have died, hospital records, autopsy re-
ports, or death certificates were examined, when possible, to es-
tablish the date and cause of death. On the whole, 90.4% of patient
accountability was determined at the end of the study.
For those patients with ascertained cause of death, each death
was classified as definitely SSc-related (death caused by organ in-
sufficiency, such as renal crisis, or by a manifestation attributable
to no other causes or predisposing factor than SSc, for example se-
vere lung fibrosis), possibly SSc-related (death caused by a mani-
festation either aggravated by SSc-related organ involvement,
such as pneumonia complicating severe lung fibrosis, or occurring
with increased frequency in SSc, for example lung cancer), and un-
related to SSc organ injury or treatment.
Statistical analysis
Cumulative survival rates were computed by the Kaplan-Meier
method (23), and the difference between survival curves by the
Mantel-Cox (log-rank) statistics using BMDP P1L (5). Survival
curves were compared to expected deaths in the age- and sex-
matched general Italian population (records from Italian ISTAT
register).
To identify potentially important prognostic variables, the indi-
vidual effect of some variables on survival was evaluated with the
use of the Cox proportional hazard regression model using BMDP
P2L (5, 9). According to a stepwise selection process, variables
were entered, or removed, from the regression equation on the ba-
sis of a computed significance probability (maximized partial like-
lihood ratio). Univariate analysis by Cox model and multivariate
analysis were also performed separately for each of the indepen-
dent variables. We examined the independent relationship to mor-
tality risk of 6 main clinico-epidemiologic variables (patient age,
sex, skin subsets, lung, heart, and kidney involvement) and 5 sero-
logic parameters (erythrocyte sedimentation rate [ESR], hemo-
globin, ACA, anti-Scl70, and ANoA). The hazard ratio for each
independent variable was expressed as the exponential of the co-
efficient of the variable in the hazard equation.
Moreover, comparisons between variables were made using
the chi-square test, with the Yates correction where appropriate.
The unpaired 2-tailed Student t-test with the Bonferroni correction
was used for multiple comparisons. A p value  0.05 was consid-
ered significant.
Results
Demographic and clinical features of 1,012 Italian
patients evaluated at the beginning and at the end of
follow-up (mean, 7.1 yr  5.7 SD) are shown in Table
3. At the last evaluation, 636 (62.8%) patients were
alive, 279 (27.6%) were known to have died, and 97
(9.6%) were considered lost to follow-up. These latter
showed the same clinico-serologic characteristics of
the 915 patients evaluated for survival study. The fe-
male/male ratio rose from 7.8 of the entire SSc popu-
lation at first visit to 10.4 of the surviving 636 patients.
At the time of diagnosis lcSSc was the most frequent
cutaneous subset; its rather high prevalence was sig-
nificantly more pronounced at the end of follow-up 
(p  .01). Similarly, the prevalence of various clinical
features referring to both living and deceased patients
(n  915) significantly increased, with the exception
of Raynaud, calcinosis, and renal involvement; only
arthritis was less frequently observed.
Table 4 shows the distribution of the main clinico-
epidemiologic features among different SSc cutaneous
subsets at diagnosis. A relatively higher percentage of
male patients was observed in both icSSc and dcSSc
than lcSSc (p  .001); disease duration calculated
from SSc onset was inversely correlated with the ex-
tent of skin sclerosis (p  0.001). In icSSc and dcSSc
several clinical manifestations were found signifi-
cantly more frequently—in particular, hypermel-
anosis, skin ulcers, arthritis, and esophageal and lung
involvement (see Table 4)—while sicca syndrome
was more commonly associated with lcSSc. The
rather high prevalence of various clinical symptoms
observed in icSSc and dcSSc was mirrored by the sig-
nificantly higher mortality rate observed in the same
subsets compared to lcSSc (p  0.001).
SSc-related autoantibodies were evaluated during
the last 2 decades in three-quarters of patients (n 
755); the prevalence of anti-Scl70, ACA, and ANoA in
the whole SSc series and their correlation with clini-
cal features are reported in Table 5. At least 1 sero-
logic marker (anti-Scl70, and/or ACA, and/or ANoA)
was detected in 89% of patients; anti-Scl70 and ACA
were mutually exclusive with the exception of 7 sub-
jects showing both autoantibodies in the same serum
sample. On the contrary, 30% of ANoA-positive pa-
tients also had serum anti-Scl70 or ACA. Disease du-
ration was comparable among 3 serologic patient
subsets. While ACA were rather frequent in females
and in lcSSc, AnoA and mostly anti-Scl70 were more
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commonly found in icSSc and dcSSc. In general, the
presence of main organ involvement did not corre-
late with serum autoantibodies; only calcinosis and
sicca syndrome were significantly more frequent in
ACA-positive, and hypermelanosis in ANoA-positive,
patients. It is noteworthy that the number of de-
ceased patients was significantly lower in ACA com-
pared to anti-Scl70 or ANoA seropositives.
Causes of death were definitely ascertained in 170
of 279 deceased patients (Table 6). A higher percent-
age of deaths was observed in males than in females
(38% vs 26%; p  .05). Heart and lung involvement,
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TABLE 3. Clinico-epidermiologic features of 1,012 Italian patients with SSc*
Beginning of End of 
Follow-Up Follow-Up p Value†
Number of patients 1,012 636 (62.8%)
Patients deceased — 279 (27.6%)
Patients lost to follow-up — 97 (9.6%)
Female/male ratio 7.8 10.4‡
Mean age (yr) 50.5  13.8 57.5  13.2
Mean disease duration (yr) 5.1  7.3 12.2  9.0
Mean follow-up (yr) 0 7.1  5.7
Limited cutaneous SSc 56 64‡
Intermediate cutaneous SSc 27 22‡ .01
Diffuse cutaneous SSc 17 14‡
Hypermelanosis 40 48 .001
Calcinosis 21 22 NS
Teleangectasias 69 79 .001
Skin ulcers 48 54 .01
Raynaud phenomenon 96 94 NS
Sicca syndrome 33 44 .001
Arthritis 19 12 .001
Esophageal involvement (X-ray) 60 68 .001
Lung involvement 60 81 .001
Heart involvement 30 35 .001
Renal involvement 7 10 NS
Abbreviations: SSc  systemic sclerosis, NS  not significant.
*Except where otherwise indicated, values are percentages.
†Comparison between the percentages of symptoms observed at the first (n  1,012) and
the last (n  915, alive  deceased) evaluation (chi-square with continuity correction).
‡Referred to 636 SSc patients still alive at the end of follow-up;
TABLE 4. Cutaneous SSc subsets and clinico-epidemiologic features at diagnosis*
a b c
lcSSc icSSc dcSSc a vs b a vs c b vs c
(n  565) (n  270) (n  177) p Value p Value p Value
Female/male ratio 12.3 9.8 2.8 NS .001 .001
Mean disease duration (yr)† 7.0  9.4 4.6  10.9 2.2  4.0 .001 .001 .001
Hypermelanosis 31 49 56 .001 .001 NS
Calcinosis 22 20 20 NS NS NS
Teleangectasias 69 72 66 NS NS NS
Skin ulcers 43 57 51 .001 NS NS
Raynaud phenomenon 96 97 94 NS NS NS
Sicca syndrome 39 24 24 .001 .001 NS
Arthritis 16 25 22 .01 NS NS
Myositis 6 5 4 NS NS NS
Esophageal involvement 55 65 69 .05 .01 NS
Lung involvement 53 65 71 .01 .001 NS
Heart involvement 23 25 32 NS .05 NS
Renal involvement 6 7 12 NS .05 NS
Deceased patients (no.) 19 35 43 .001 .001 NS
Abbreviations: SSc  systemic sclerosis; lcSSc  limited cutaneous scleroderma; icSSc  intermediate cutaneous scleroderma; dcSSc 
diffuse cutaneous scleroderma; NS  not significant.
*Except where otherwise indicated, values are percentages.
†Calculated from disease onset.
alone or in association, were the most frequent com-
plications (69%) affecting the overall disease out-
come. Other important but less frequent causes of
death were cancer and severe renal involvement.
Survival rates
At the first clinical evaluation the 3 SSc series show
a comparable composition with regards to patient
mean age, sex, and cutaneous subsets. However, dif-
ferent 10th year survival rates were observed among
the 3 patient series. Worse cumulative survivals were
observed in older SSc series with regards to the year
of beginning of the follow up; in particular, the
Napoli series showed 63% survival, Pisa 70.4%, and
Padova 78.2%. When calculated only for patients re-
cruited after 1985 these differences were less pro-
nounced (72%, 76%, and 82%, respectively).
The results of the survival study are summarized in
Table 7. Cumulative survival of the whole SSc series
of 1,012 patients (Figure 4), calculated from the time
of diagnosis, showed an almost constant decrease,
with rates of 69.2% and 45.5% at the 10th and 20th year,
respectively. The observed survival rates were signif-
icantly lower than those expected in the Italian age-
and sex-matched general population (p  .00001).
When calculated from disease onset, a significantly
higher 10th-year survival was found (87.8% vs 69.2; 
p  .0001; see Table 7). Survival from disease onset
was also calculated in those patients with disease du-
ration 2 years, recruited after 1985. In this particular
subgroup the 10th-year survival from disease onset
was comparable to that observed from diagnosis in
the whole SSc series (76.9% vs 76.8%; see Table 7 and
Figure 9). The prognostic relevance of patient age at
the time of disease onset was evaluated by calculating
survival rates in 3 subgroups of patients aged 35
years, from 36 to 50 years, and 50 years. The 10th-
year survivals observed among these subgroups were
79.6%, 71.6%, and 60.5%, respectively (p  .0001), sig-
nificantly lower than those expected in age- and sex-
matched groups from the Italian general population (p
 .00001). Moreover, male patients had a worse prog-
nosis than females (p  .00001; Figure 5); both male
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TABLE 5. Correlation between SSc-related autoantibodies and clinico-epidemiologic features*
a b c a vs b a vs c b vs c
anti-Scl70 ACA ANoA p Value p Value p Value
Percentage of total SSc series 36 39 20
Female/male ratio 7.9 17.1 8.8 .02 ns .05
Mean disease duration (yr)† 5.2  7.5 5.1  7.9 5.2  7.8 ns ns ns
Cutaneous subsets†
Limited cutaneous SSc 25.3 53 12.8 .001 .001 .001
Intermediate cutaneous SSc 51.3 21.8 22.8 .001 .001 ns
Diffuse cutaneous SSc 58.6 11.3 17.5 .001 .001 ns
Clinical features‡
Hypermelanosis 38 31 48 ns .05 .001
Calcinosis 16 26 16 .01 ns .02
Teleangectasias 69 69 71 ns ns ns
Skin ulcers 51 42 50 .05 ns ns
Raynaud phenomenon 96 98 97 ns ns ns
Sicca syndrome 34 44 31 .05 ns .01
Arthritis 17 14 22 ns ns .05
Myositis 3 4 6 ns ns ns
Esophageal involvement 70 68 68 ns ns ns
Lung involvement 61 58 61 ns ns ns
Heart involvement 19 23 24 ns ns ns
Renal involvement 7 7 2 ns ns .05
Deceased patients (%) 20 11 24 .01 ns .001
Abbreviations: SSc  systemic sclerosis; ACA  anti-centromere; ANoA  anti-nucleolar autoantibodies.
*Except where otherwise indicated, values are percentages.
†At diagnosis.
‡Evaluated at the end of follow-up.
TABLE 6. Causes of death
No. of patients deceased 279/915 (30.4%)
Females/males 5.3 (235/44)
Causes of Death No. (%)
Unknown 109
Known 170
Heart involvement 62 (36)
Lung involvement 40 (24)
Heart  lung involvement 15 (9)
Cancer 25 (15)
Kidney involvement 21 (12)
Miscellaneous 7 (4)
SSc-related 36%
Possibly SSc-related 52%
Not SSc-related 12%
and female SSc patients showed a significantly lower
survival compared to the corresponding groups from
the general population. The extent of cutaneous
sclerosis was significantly correlated with survival 
(p  .00001). Moreover, the survival curve of icSSc
was equidistant from both the lcSSc and dcSSc sub-
sets (Figure 6). Using the 2-cutaneous subset classifi-
cation, statistically different 10th-year survival rates
were again observed for lcSSc and dcSSc (p  .00001).
In patients with Raynaud duration  or 1 year, at
the time of disease onset, significantly different 10th-
year survival rates calculated from diagnosis were
observed (67.9% vs 73.4%, p  .0164).
The presence of main organ involvement (lung,
heart, and kidney) was associated with significantly
lower survival rates; the worst 10th-year survival rate
was observed for patients with renal involvement
and for a group of 21 patients with simultaneous
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TABLE 7. Survival rates in different patient subsets
10th-Year Survival Rate
(%) p Value
Cumulative from diagnosis 69.2 .0001
Cumulative from SSc onset 87.8
SSc duration 2/2 yr* 76.9/92.8 .00001
Patients aged 35/36–50/50 yr 79.6/71.6/60.5 .0001
Male/female 53.2/71.6 .00001
Limited/intermediate/diffuse 78.3/65.5/52.2 .00001
Limited/diffuse 75.1/53.4 .00001
Raynaud duration 1/1 yr 67.9/73.4 .0164
Lung involvement / 64.9/80.6 .00001
Heart involvement / 59.1/77 .00001
Renal involvement / 34.8/74.6 .00001
Lung & heart & renal involvement / 12.6/86.5 .00001
Anti-Scl70‡ / 72.2/80.8 .0525
ACA‡ / 85.9/72.7 .0004
ANoA‡ / 72.6/80.3 NS
Patients recruited 1955–85/1986–99 60.6/76.8 .0001
*Survival calculated from disease onset in patients recruited after 1985.
‡Survival calculated from diagnosis in patients recruited after 1985.
FIG. 4. Cumulative survivals at 10th and 20th year (69.2% and
45.5%, p  .00001) from diagnosis in 1,012 SSc patients compared
to expected survival (80.6%) in the Italian general population (p 
.00001).
FIG. 5. Survival rates in female and male patients (71.6% vs
53.2%, p  .00001) were significantly lower than expected survival
rates (p  .00001).
lung, heart, and kidney involvement (Figure 7; see
Table 7). No statistically significant differences were
observed in SSc subsets classified according to pres-
ence/absence of serum anti-Scl70 or ANoA, while
ACA-positive patients were characterized by a better
prognosis compared with ACA-negative patients
(Figure 8; see Table 7).
The results of univariate and multivariate survival
analysis by Cox proportional hazards model (Table
8) further support some of the above prognostic find-
ings obtained by Kaplan-Meier survival curves. We
analyzed 6 main variables (patient age, sex, skin sub-
sets, lung, heart, and kidney involvement) in a large
group of 914 SSc patients (other variables were fre-
quently missing values, so they were not analyzed in
this group). All variables were associated with in-
creased risk of mortality at univariate analysis, often
confirmed by multivariate analysis. In particular, by
means of univariate analysis, for every increase in
year of age there was a 4% increase in mortality risk;
male gender showed an 82% increase mortality; lung,
heart, and kidney involvement a 102%, 112%, and
340% increase, respectively. All cutaneous subsets
showed an increased mortality risk, which was cor-
related to the extent of skin sclerosis: in dcSSc the
excess of mortality was 3 times that observed in
lcSSc. The analysis of 529 patients, including sero-
logic parameters, demonstrated that increased ESR
at diagnosis (25 mm/h) was associated with 93% ex-
cess mortality, while the presence of serum ACA was
associated with a lower mortality risk (see Table 8).
Finally, the survival study focused on the possible
variations of SSc outcome during the last few
decades; in this respect, survival rates were evalu-
ated by subdividing the whole SSc series in 2 groups
according to different time intervals of enrollment. 
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FIG. 7. Survival rates in different visceral organ involvement (L:
lung; H: heart; K: kidney). The presence () of visceral organ in-
volvement was associated with significantly worse survival rates
compared with the absence (-) thereof; see also Table 7.
FIG. 8. Survival rates in patients with () or without (-) serum
autoantibodies (Scl70: anti-Scl70; ACA: anti-centromere; ANoA:
anti-nucleolar).
FIG. 6. Survival rates in cutaneous SSc subsets classified ac-
cording to the 2-subset model (limited [lSSc] and diffuse [dSSc])
or the 3-subset model (limited [lSSc], intermediate [iSSc], and dif-
fuse [dSSc]).
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In particular, patients recruited from 1986 to 1999
showed a significantly higher 10th-year survival rate
compared with those recruited from 1955 to 1985
(76.8% vs 60.6%; p  .0001) (Figure 9; see Table 7).
The 10th-year survival rate observed in the present
SSc population was comparable to the mean value of
survival rates found in other SSc series reported dur-
ing the last decade (69.2% vs 72.0%; Table 9). In this
respect, the mean survival rate observed in the older
reports was significantly lower than that found in
more recent studies (1–3, 6, 10–14, 16, 20, 24, 25, 27,
29, 33, 37) (see Table 9).
Discussion
This multicenter, retrospective follow-up study
evaluated clinico-epidemiologic and prognostic pa-
rameters in a large Italian SSc patient population. A
number of demographic and clinical features con-
firmed in part the observations of previous reports
(1, 2, 6, 11–14, 20, 28, 31). In particular, the disease
more frequently affects middle-aged females; limited
cutaneous involvement represents the most frequent
clinical variant; and SSc multisystem involvement
shows a significant progression over follow-up. The
prevalence of many features such as lung, heart, and
esophageal involvement was significantly increased
at the last patient evaluation; consequently, a fatal
outcome was recorded in over one-quarter of pa-
tients. SSc could be directly or indirectly responsible
for death in the majority of cases; cardiopulmonary
involvement and cancer were the most frequent
causes of death, while severe renal involvement was
observed in a relatively small number of deceased pa-
tients. The prevalence of nephropathy in our SSc pa-
tients and its relative percentage among causes of
death are smaller compared to other series from
Northern Europe or the United States (1, 14); while a
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FIG. 9. Cumulative survival rates in patients recruited during
1955–1985 and 1986–1999, respectively.
TABLE 9. Survival studies in systemic sclerosis patients
10th-year First Author, Year (ref.) Country Referral Center Recruitment Period No. of Patients
Survival (%)
Older Studies
Tuffanelli, 1961 (33) US Dermatology 1935–58 727 59
Bennett, 1971 (3) UK Rheumatology 1947–70 67 40
Medsger, 1971 (20) US Rheumatology 1955–70 309 35
Rowell, 1976 (27) UK Dermatology 1960–75 84 74
Altman, 1991 (1) US Rheumatology 1973–77 264 42
Barnett 1988 (2) Australia Rheumatol 1953–78 113 55
Eason 1981 (10) New Zealand Internal Medicine 1970–80 47 42
Wynn 1985 (37) US Internal Medicine 1970–80 64 51
Giordano 1986 (12) Italy Rheumatology 1963–83 90 32
More Recent studies
Ferri 1991 (11) Italy Rheumatology 1972–89 151 65
Lee 1992 (16) Canada Rheumatology 1979–90 237 61
Simeon 1997 (29) Spain Internal Medicine 1980–90 72 85
Bryan 1996 (6) UK Rheumatology 1982–92 283 75
Nagy 1997 (24) Hungary Internal Medicine 1982–93 171 70
Nishioka 1996 (25) Japan Dermatology 1974–94 496 82
Hesselstrand 1998 (13) Sweden Rheumatology 1983–95 249 69
Jacobsen 1998 (14) Denmark Rheumatology 1960–96 344 71
Present report Italy Rheumatology 1955–99 1,012 69
Mean survival in older studies 47.8  13.3
Mean survival in more recent studies 72.0  7.60
p  .0005
comparable prevalence of renal involvement was re-
ported in other patient series from the Mediterranean
area (29, 35). Besides other unknown genetic and/or
environmental cofactors, the discrepancy in the pre-
valence of renal involvement among various SSc pa-
tient populations might be correlated to different
climatic conditions, potentially relevant for the de-
velopment of this complication.
Survival study demonstrated a statistically higher
mortality in SSc patients compared to the Italian gen-
eral population; the percentage of surviving patients
showed an almost linear decrease during a 20-year
follow-up period. The worst prognostic parameters
were the male gender, a wide extent of skin sclerosis,
and the presence of main visceral organ involvement,
that is, heart, lung, and kidney. Another useful prog-
nostic indicator was the time interval between the
appearance of Raynaud phenomenon and the onset 
of scleroderma: a shorter Raynaud duration at the
disease onset significantly correlated with a worse
survival. With regards to the serologic markers, a rela-
tionship between the presence of ACA or anti-Scl70
and the extent of skin sclerosis was observed; namely,
ACA were significantly more frequent in lcSSc, and
anti-Scl70 in both icSSc and dcSSc subsets. More in-
terestingly, the survival study suggested a “protective”
role of ACA; as observed in previous studies, a better
prognosis was found in ACA-positive individuals (15,
17, 19, 28, 31). On the contrary, patients with anti-Scl70
and/or ANoA showed a significantly higher percentage
of deaths compared to ACA seropositives.
The analysis by Cox proportional hazards model
further stressed the prognostic relevance of the
above parameters. An increased mortality risk was
correlated with male gender, extent of skin sclerosis,
presence of lung, heart, and renal involvement; com-
parable findings have been found in other patient se-
ries from the United States and the United Kingdom
(1, 7).
However, some important differences emerged
with regards to the prevalence of clinico-serologic
features and survival rates among various series
from different countries, as well as between the pre-
sent SSc series and previous studies (1–3, 6, 10, 13,
14, 16, 20, 24, 25, 27, 29, 33, 37; see Table 9). It is of-
ten difficult to explain these discrepancies; racial
and/or environmental etiopathogenetic factors, and
not secondarily different methodologic approaches,
among referral centers should be taken into account.
There is unanimous agreement to consider the ex-
tent of skin sclerosis as the most useful clinico-prog-
nostic tool (2, 11, 12, 17–19, 28, 31). In the absence of
other more specific and sensible clinico-serologic pa-
rameters, the SSc classification in cutaneous subsets
represents a feasible and useful indicator, particu-
larly at the initial patient assessment. The present
study further supports our previous observation sug-
gesting a better discriminating power of the 3-subset
classification (11, 12). In fact, patients with lcSSc,
corresponding to sclerodactyly, showed a signifi-
cantly lower mortality rate with a better 10th-year
survival compared to patients with either icSSc or 
dcSSc. These latter 2 subsets shared a number of
clinico-serologic features, that is, the prevalence of
skin ulcers, arthritis, esophageal and lung involve-
ment, and anti-Scl70 seropositivity, together with the
percentage of deceased patients. On the contrary, the
presence of sclerodactyly, with or without sclerosis
of the neck and/or face, seems to identify a subgroup
of patients with the best prognosis. For future clini-
cal investigations, a uniform classification of SSc
patients should be adopted by different referral cen-
ters. Following either the 2- or 3-subset model, it
might be opportune to group subjects with very lim-
ited skin sclerosis (sclerodactyly) in a subset with
peculiar clinico-serologic and prognostic features.
Compared with other connective tissue diseases,
SSc is characterized by a higher mortality rate. The
fatal outcome may be the consequence of severe sin-
gle organ injury, mainly kidney, lung, or heart, or
more often it may be the result of the combined in-
volvement of various internal organs. Thus, a single
clinical manifestation, even the extent of cutaneous
sclerosis, is not necessarily a valid prognostic indi-
cator in a given patient. In this respect, survival stud-
ies on large SSc series can give us new insights on the
prognostic relevance of different clinico-serologic
parameters. However, various authors have pointed
out the difficulties in interpreting survival data from
different patient populations because of their fre-
quent heterogeneity (6, 13, 28). The correct approach
to retrospective survival studies is still controversial.
Two kinds of problems remain to be resolved: the
modality of patient selection and the survival calcu-
lation. SSc is a relatively rare disorder, characterized
by a wide spectrum of clinical symptoms; very mild
to moderate clinical variants are rather common. It is
likely that the more severe cases are concentrated in
referral centers; consequently, the actual mortality
from scleroderma, evaluated in patients attending
specialist centers, may be overestimated. In addition,
the correct evaluation of the natural history of the
disease implies the calculation of the disease dura-
tion from disease onset to death. However, this ap-
proach could be misleading. First, there is a long
delay between the clinical onset and the diagnosis,
especially for slow progressive SSc variants; in these
cases it is often arbitrary to name a date for the
disease onset, even for the patients themselves.
Moreover, this modality introduces an important
methodologic error, the so called immortality bias
(18); patients referred to specialist centers did not
represent the entire SSc population, but a surviving
cohort. Therefore, the survival calculated from dis-
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ease onset invariably underestimated the true mor-
tality from SSc. In recent years, an increasing num-
ber of patients with early SSc have been referred to
Italian specialist centers due to the better knowledge
of the disease by general practitioners and patients
themselves, as well as the wide diffusion of some di-
agnostic tools, such as capillaroscopy. In the future,
prospective studies on patient populations referred
early in the course of the disease could minimize the
above-mentioned problems.
In the present study we have attempted to over-
come these difficulties, at least in part, by evaluating
the survival in those patients with early SSc (2
years), referred to the 3 Italian centers after 1985.
This particular subgroup of patients, whose recalled
date of disease onset was sufficiently reliable, could
better reflect the actual composition of the SSc spec-
trum. Surprisingly, the 10th-year survival calculated
from disease onset in this subgroup (76.9%) was sim-
ilar to that obtained from diagnosis in the whole SSc
series (76.8%). It is difficult to explain the signifi-
cance of this latter observation. One possible inter-
pretation could be that cumulative SSc survival
calculated from diagnosis is burdened with 2 oppo-
site factors: the concentration in referral centers of a
population with more severe disease and rather high
mortality, on the 1 side, and the presence of a “sur-
viving” SSc cohort with better prognosis, on the
other side. Due to the above counterbalancing fac-
tors, the survival rates calculated from diagnosis, as
usually reported in retrospective studies, might suffi-
ciently reflect the actual outcome of the disease.
Different survival rates observed in our 3 patient
series showed a north-south gradient. A possible role
of genetic and/or environmental cofactors in differ-
ent series can be reasonably excluded on the basis 
of the following considerations. Compared to the
Padova series, patients in the Pisa and especially the
Napoli series had been recruited over a wider time in-
terval, including the 1950s and 1960s, when a rela-
tively higher percentage of patients with more severe
SSc were referred to specialist centers. If evaluated
only in patients referred to the 3 centers after 1985,
comparable 10th-year survival rates were demon-
strated among the 3 SSc populations. As mentioned
above, more severe SSc variants were probably con-
centrated in referral centers during the last 4–5
decades. This possibility could be indirectly sup-
ported by the better survival rates medially observed
in more recent studies compared with previous re-
ports. The improved prognosis among various SSc
patient populations seems to be independent of dif-
ferent racial and/or environmental pathogenetic co-
factors and/or different methodologic approaches
(1–3, 6, 10–14, 16, 20, 24, 25, 27, 29, 33, 37). It is pos-
sible to hypothesize that the improved SSc outcome,
largely observed during the last years, could be re-
lated to a wider patient recruitment at specialist cen-
ters, which better reflects the entire scleroderma
spectrum. Moreover, the possible contribution of re-
cently available treatments also should be taken into
account (4, 19, 30, 36). The treatment of SSc is com-
monly divided into 2 broad headings: treatment of or-
gan manifestations, that is, scleroderma renal crisis,
esophageal, lung or heart involvement, and digital
ulcerations, and disease-modifying therapy aimed at
influencing the pathogenetic process (Table 10). De-
spite the present lack of any drug or combination of
drugs clearly effective as disease-modifying therapy
(4), some significant advances have been reached in
the last 20 years in treating organ-based manifesta-
tions (4). In this respect, some studies have pointed
out the efficacy of cyclophosphamide in the treatment
of fibrosing alveolitis in its early inflammatory stage.
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TABLE 10. Treatment of systemic sclerosis
Proposed Disease-modifying Therapies Organ Manifestation Treatments
Antilymphocyte globulin Raynaud phenomenon  active skin ulcers
Antithymocyte globulin Ca-channel blockers, iloprost, aspirin
Autologous stem cell transplantation Scleroderma renal crisis
Azathioprine ACE inhibitors, dialysis
Clorambucil Cardiac involvement
Colchicine ACE inhibitors, antiarrhythmics, pacemaker, steroids (pericarditis)
Cyclophosphamide Pulmonary hypertension
Cyclosporin A Iloprost, prostacyclin, oral anticoagulation
D-penicillamine Lung involvement
Interferon-alpha Cyclophosphamide, oxygen, lung transplant
Interferon-gamma Esophageal, intestinal involvement
Methotrexate Prokinetics, omeprazole, antibiotics
Photoapheresis Articular involvement, myositis
Plasmapheresis Low-dose steroids
Skin sclerosis
Emollients, exercises
Abbreviations: ACE  angiotension-converting enzyme inhibitors.
The extreme variability of SSc prevents us from iden-
tifying a treatment useful for all patients. Actually, the
therapy must be tailored to the individual patient de-
pending on the extent and severity of organ involve-
ment and the pathophysiologic stage of the disease,
that is, active-evolutive or inactive-stable SSc.
Summary
In this multicenter, retrospective study we evaluate
the clinico-epidemiologic and prognostic features of
a large Italian systemic sclerosis (SSc) series (1,012
patients, 897 females and 115 males; mean age at pre-
sentation, 50.5 yr  13.8 SD; mean follow-up, 7.1 yr 
5.7 SD) recruited between 1955 and 1999 at 3 univer-
sity-based rheumatology units, from the north (Uni-
versity of Padova), center (University of Pisa), and
south (University of Napoli) of Italy. Limited cuta-
neous SSc was the most frequent subset with the best
prognosis independent of the classification used,
based on skin sclerosis extent (2- or 3-subset models).
The percentages of various organ involvement signif-
icantly increased at the last patient evaluation. The
progression of the disease during follow-up was mir-
rored by the constant decrease in the cumulative sur-
vival rates (Kaplan-Meier method) calculated at the
10th and 20th year from diagnosis (69.2% and 45.5%,
respectively, p  .00001); the observed SSc survival
rates were significantly lower than those expected in
the Italian general population (p  .00001). 
Among SSc patients, significantly worse prognosis
was observed in the diffuse cutaneous subset (p 
.00001), in male gender (p  .00001), and in patients
with lung (p  .00001), heart (p  .00001), and renal
involvement (p  .00001). A shorter duration of Ray-
naud phenomenon before the scleroderma onset was
correlated with worse outcome (p  .0164). With re-
gards to serologic markers, the presence or absence
of anti-centromere antibody was an important prog-
nostic indicator (85.9% vs 72.7% 10th-year survival,
respectively; p  .0004). Univariate and multivariate
analysis by Cox proportional hazard regression
model further confirmed the results of survival study:
the mortality risk was significantly increased in male
patients; in patients with diffuse cutaneous SSc; in
patients with lung, heart, and kidney involvement;
and in patients with abnormally high erythrocyte sed-
imentation rate (ESR) (25 mm/h) evaluated at pa-
tient enrollment. Thirty percent of patients died
during the follow-up period; the most frequent
causes of death were cardiac (36%) and lung (24%) in-
volvement, and cancer (15%). Deaths were definitely
or possibly related to SSc in 36% and 52% of cases, re-
spectively. Renal involvement was a relatively rare
complication in Italian SSc patients; comparable fea-
tures were observed in other SSc populations from
the Mediterranean area.
Patients recruited after 1985 showed a signifi-
cantly better 10th–year survival rate compared with
subjects referred before 1985 (76.8% vs 60.6%, p 
.0001). Comparable survival rates have been re-
ported in recent studies on SSc series from other
countries. This finding could be related to the wider
recruitment of mild-to-moderate clinical variants at
specialist centers, which better reflects the entire
scleroderma spectrum, and, not secondarily, to the
possible contribution of recently available therapies.
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